Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury
Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases — for example, in different forms of crescentic glomerulonephritis — because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3+CD4+ T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody–associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4+ T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3+CD4+ T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCI Insight - 8(2023), 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jan-Hendrik Riedel [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ091030099 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091030099 | ||
| 003 | DE-627 | ||
| 005 | 20240413222636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ091030099 | ||
| 035 | |a (DE-599)DOAJ6443c52a90ff43ecadb3bda903f06ac0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Jan-Hendrik Riedel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases — for example, in different forms of crescentic glomerulonephritis — because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3+CD4+ T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody–associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4+ T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3+CD4+ T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology. | ||
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Nephrology | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Lennart Robben |e verfasserin |4 aut | |
| 700 | 0 | |a Hans-Joachim Paust |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a Nariaki Asada |e verfasserin |4 aut | |
| 700 | 0 | |a Ning Song |e verfasserin |4 aut | |
| 700 | 0 | |a Anett Peters |e verfasserin |4 aut | |
| 700 | 0 | |a Anna Kaffke |e verfasserin |4 aut | |
| 700 | 0 | |a Alina Borchers |e verfasserin |4 aut | |
| 700 | 0 | |a Gisa Tiegs |e verfasserin |4 aut | |
| 700 | 0 | |a Larissa Seifert |e verfasserin |4 aut | |
| 700 | 0 | |a Nicola M. Tomas |e verfasserin |4 aut | |
| 700 | 0 | |a Elion Hoxha |e verfasserin |4 aut | |
| 700 | 0 | |a Ulrich O. Wenzel |e verfasserin |4 aut | |
| 700 | 0 | |a Tobias B. Huber |e verfasserin |4 aut | |
| 700 | 0 | |a Thorsten Wiech |e verfasserin |4 aut | |
| 700 | 0 | |a Jan-Eric Turner |e verfasserin |4 aut | |
| 700 | 0 | |a Christian F. Krebs |e verfasserin |4 aut | |
| 700 | 0 | |a Ulf Panzer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t JCI Insight |d American Society for Clinical investigation, 2020 |g 8(2023), 1 |w (DE-627)DOAJ078602696 |x 23793708 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |
| 856 | 4 | 0 | |u https://doaj.org/article/6443c52a90ff43ecadb3bda903f06ac0 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1172/jci.insight.160251 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2379-3708 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 | ||